A Phase 3 interventional study of Botulinum Toxin: Xeomin and Placebo in Parkinson's Disease and Foot Dystonia, sponsored by University Hospital, Clermont-Ferrand. Completed at 4 sites in France. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by University Hospital, Clermont-Ferrand · Phase 3, Interventional, and Treatment
Rieu I, Degos B, Castelnovo G, Vial C, Durand E, Pereira B, Simonetta-Moreau M, Sangla S, Fluchere F, Guehl D, Burbaud P, Geny C, Gayraud D, Ory-Magne F, Bouho…PubMed 29102441 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand — 5 open to participants now, 5 under way, none of them phase 3. Parkinson Disease · University Hospital, Clermont-Ferrand.
Among the 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand, this one is the 13th largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2010, is the only one in phase 3, and was the 4th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →5 of the 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–75 · Healthy volunteers
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–90
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–80
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 46 across the 23 interventional studies, 250 across the 2 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
2 of the studies in Parkinson Disease by University Hospital, Clermont-Ferrand that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07702266University Hospital, Clermont-FerrandPrimary Parkinsonian Pain: Clinical Association and Phenotype | 2027-09-30 |
| NCT07813156University Hospital, Clermont-FerrandIdiopathic Parkinson's Disease: Interest of an Early Group-Based Cognitive Rehabilitation Program (LIFECOG-PD) | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Foot dystonia is frequently observed in patients suffering from Parkinson'disease. It is characterized by an abnormal involuntary movement which is very uncomfortable (difficult to walk) and painful for the patient.
Botulinum toxin injections seem to be efficient to treat this dystonia. However studies on this topic are few and very imprecise (many muscle injected, especially the Flexor digitorum longus, different doses used, heterogeneous population with many types of dystonia included, open studies).
Study progress :
After an inclusion visit, patients are randomized in one of the 3 following groups :
First group (PL : placebo) :
Second group (ME : Extrinsic muscle)
Third group (MI : Intrinsic muscle)
During injections (J0 and J+3M), we will measure the pain induced by injections (EVA) For each evaluation (J+1M and J+4M), following evaluations will be made: clinical improvement (CGI), dystonia evaluation (duration and severity, Burke scale), pain (EVA) and quality of life (PDQ39).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
45 patients with an Idiopathic Parkinson's disease and a foot dystonia. Double blind, randomized study
Placebo injection
In a controlled double blind and randomized study, we want to show that intramuscular injections of botulinum toxin are beneficial to reduced dystonia and associated pain in patient with foot dystonia (compared to placebo injections).
Time frame: one month after the injection of botulinum toxin/placebo
Efficiency comparison of injections made in leg muscle (Flexor digitorum longus) between injections made directly in foot muscle (Flexor digitorum brevis or quadratus plantae) - Effects of injections on pain and quality of life.
Time frame: one month after injections of placebo or Botulinum toxin
Ran from Feb 2010 to primary completion in Nov 2013, 44 months.
Of 68 phase 3 interventional studies under Parkinson Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 44 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Sep 2009 → Feb 2010, primary completion Sep 2011 → Nov 2013 and completion Sep 2012 → Feb 2014.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Rieu I, Degos B, Castelnovo G, Vial C, Durand E, Pereira B, Simonetta-Moreau M, Sangla S, Fluchere F, Guehl D, Burbaud P, Geny C, Gayraud D, Ory-Magne F, Bouho…PubMed 29102441 ↗
Rieu I, Degos B, Castelnovo G, Vial C, Durand E, Pereira B, Simonetta-Moreau M, Sangla S, Fluchere F, Guehl D, Burbaud P, Geny C, Gayraud D, Ory-Magne F, Bouho…PubMed 29102441 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A
University Hospital, Clermont-Ferrand →